Related Experiment Video

Updated: May 10, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Propranolol intervention therapy for infants with facial hemangioma

Jian Meng1, Zhiping Li, Qianping Gu

  • 1Department of Dentistry, Central Hospital of Xuzhou City, China.

Contemporary Oncology (Poznan, Poland)
|June 22, 2013
PubMed

Insights

Small doses of propranolol effectively treat infantile facial hemangioma in infants. This treatment shows a 100% effective rate with minimal side effects, making it a safe and convenient option.

Area of Science:

  • Pediatric Dermatology
  • Pharmacology

Background:

  • Infantile facial hemangioma is a common vascular tumor in infants.
  • The proliferation stage requires effective and safe treatment interventions.

Purpose of the Study:

  • To evaluate the clinical efficacy of low-dose propranolol for infantile facial hemangioma.
  • To assess the adverse effects associated with this treatment in infants.

Main Methods:

  • A cohort of 22 infants with facial hemangioma received propranolol (1.0-1.5 mg/kg/day).
  • Treatment efficacy and adverse events were monitored over 3-9 months post-discharge.

Main Results:

  • Hemangioma color faded within 24 hours of propranolol administration.
  • A 100% effective treatment rate was observed across all patients.
  • Minor side effects, including slowed heart rate and transient diarrhea, were reported in some patients.

Conclusions:

  • Low-dose propranolol is a safe and effective treatment for infantile facial hemangioma.
  • The treatment offers convenience and minimal adverse effects.
  • Propranolol represents a valuable therapeutic option for infants with proliferating hemangioma.
Abstract

Keywords:
hemangiomainfantspropranolol

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...